

## Supplementary information

### Title:

Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus

### Author list:

Ryosuke Ono,<sup>1</sup> Fumitaka Nishimae,<sup>1</sup> Takuro Wakida,<sup>1</sup> Fuminori Sakurai,<sup>1,\*</sup> and Hiroyuki Mizuguchi<sup>1,2,3,4,5,\*</sup>

<sup>1</sup> Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

<sup>2</sup> Laboratory of Functional Organoid for Drug Discovery, Center for Drug Discovery Resources Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan

<sup>3</sup> Global Center for Medical Engineering and Informatics, Osaka University, Osaka, Japan

<sup>4</sup> Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka, Japan




<sup>5</sup> Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan

Supplementary figure S1.

The luciferase expression levels in human cultured cells following treatment with Ad-L2 and OAd-tAIB-Luc

A) H1299 B) HeLa C) PANC1 cells were transduced with Ad-L2 and OAd-tAIB-Luc at 200 VP/cell. The luminescence (relative light unit) was measured on day 3. These data of luminescence were used as a control and normalized to 100% in Fig. 1. These data are expressed as the means  $\pm$  SD. (n=4).

# Supplementary figure S1



Supplementary figure S2.

Cell viabilities on day 3 following treatment with OAd-tAIB-Luc.


A) H1299 B) HeLa C) PANC1 cells were treated with OAd-tAIB-Luc at 200 VP/cell. Cell viabilities were determined on day 3. The cell viabilities of mock-treated cells were normalized to 100%. These data are expressed as the means  $\pm$  SD. (n=4) and analyzed by one-way ANOVA followed by Dunnett's multiple comparisons test. \*,  $P < 0.05$ , \*\*,  $P < 0.01$ , \*\*\*,  $P < 0.001$ , n.s.; not significant =  $P > 0.05$ . (vs. No serum group).

# Supplementary figure S2

Anti-Ad5 neutralizing antibody titer

Low

High



Supplementary figure S3.

Cell viabilities on day 10 following treatment with OAd-tAIB-Luc.

A) H1299 B) HeLa C) PANC1 cells were treated with OAd-tAIB-Luc at 200 VP/cell. Cell viabilities were determined on day 10. The cell viabilities of mock-treated cells were normalized to 100%. These data are expressed as the means  $\pm$  SD. (n=4) and analyzed by one-way ANOVA followed by Dunnett's multiple comparisons test. \*,  $P < 0.05$ , \*\*,  $P < 0.01$ , \*\*\*,  $P < 0.001$ , n.s.; not significant =  $P > 0.05$ . (vs. No serum group).

# Supplementary figure S3

Anti-Ad5 neutralizing antibody titer

Low

High

